Oman Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Oman Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Oman Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: Oman's evolving demographic and epidemiological profile will act as key drivers of growth within the country's pharmaceuticals and healthcare markets over the coming years - shaping opportunities for multinational pharmaceutical companies. The rollout of a compulsory health insurance scheme, promotion of medical tourism and greater international collaboration will boost the private sector's contribution to healthcare in Oman. Over the long term, however, the public sector will remain the dominant healthcare p l ayer as the rapidly growing demand for healthcare services necessitates high levels of government commitment.

Headline Expenditure Projections

  • Pharmaceuticals: OMR244mn (USD634mn) in 2015 to OMR257mn (USD668mn) in 2016; +5.3% in local currency and US dollar terms. Forecast in line with Q 4 16.

  • Healthcare: OMR1.14bn (USD2.96bn) in 2015 to OMR1.19bn (USD3.08bn) in 2016; +3.9% in local currency and US dollar terms. Forecast in line with Q 4 16.

Headline Pharmaceuticals & Healthcare Forecasts (Oman 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: UN Comtrade, national sources, BMI
Pharmaceutical sales, USDbn 0.588 0.634 0.668 0.705 0.745 0.789 0.836
Pharmaceutical sales, % of GDP 0.72 0.87 0.89 0.91 0.92 0.93 0.94
Pharmaceutical sales, % of health expenditure 20.6 21.4 21.7 22.0 22.3 22.6 23.0
Health spending, USDbn 2.856 2.965 3.082 3.207 3.342 3.487 3.643

Risk/Reward Index

In our Q117 Pharmaceutical Risk/Reward Index (RRI) Oman's score of 47.6 out of 100 matches its score last quarter, and maintains its position in 11th place out of 31 countries analysed in the whole Middle East and Africa (MEA) region. Regionally, Oman ranks relatively poorly compared to the other Gulf States - only Iraq is positioned lower. Oman has limited longer-term commercial potential due to its small population, low per capita spending on pharmaceuticals and the fact that the government is responsible for the bulk of healthcare costs, which will increase the need for cost containment in the coming years. However, Oman's well-established intellectual property regime and exemplary business environment will boost Oman's attractiveness as an investment destination.

Latest Updates

  • In November 2016, the Omani government announced plans to create a Medical City Investment Fund, to support the establishment of a world-class tertiary healthcare and medical education hub.

  • In October 2016, UAE-based Julphar pharmaceuticals launched two new diabetes medicines in countries that included Oman, through the assistance of a supply and co-marketing agreement with Merck Sharp & Dohme.

  • Omanexpo is organising the sixth Oman Health Exhibition Conference in September 2016 in a bid to attract more drugmakers to set up in Oman.

BMI Economic View

Growth of Oman's economy will slow over H216 and 2017, as the slump in global energy prices begins to have a larger impact on the private sector and the government starts to take more extensive steps to control public spending. Tightening liquidity conditions, reduced fiscal support, and weak export growth will present headwinds for corporates. Progress on public infrastructure projects will remain a key source of support for construction activity and domestic demand, but to a lesser extent than in recent years. We forecast real economic growth at 2.3% for 2016 and 2.5% in 2017, compared to the annualised rate of 4.0% recorded between 2010 and 2015.

BMI Political View

The escalating tensions between Iran and Saudi Arabia threaten to undermine Oman's long held position of regional neutrality. Although the country's careful balance between Tehran and the rest of the Gulf is likely to be maintained as long as Sultan Qaboos bin Said is in power, his successor could struggle to navigate the same middle ground.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Oman 2014-2020)
7
SWOT
9
Industry Forecast
12
Pharmaceutical Market Forecast
12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Oman 2012-2020)
14
Healthcare Market Forecast
15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2012-2020)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2012-2020)
17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2012-2020)
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Oman 2012-2020)
20
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Oman 2012-2020)
22
Generic Drug Market Forecast
23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Oman 2012-2020)
24
OTC Medicine Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Oman 2012-2020)
26
Pharmaceutical Trade Forecast
27
Table: Pharmaceutical Trade Data And Forecasts (Oman 2014-2020)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Oman 2014-2020)
29
Industry Risk/Reward Index
30
Middle East and Africa Risk/Reward Index - Q3 2016
30
Oman Risk/Reward Index
38
Rewards
38
Risks
39
Regulatory Review
41
Intellectual Property Issues
42
Pricing Regime
43
Reimbursement Regime
45
Market Overview
46
Healthcare Sector
47
Table: Healthcare Resources (Oman 2010-2015)
49
Table: Healthcare Personnel (Oman 2010-2015)
49
Table: Healthcare Activity (Oman 2010-2015)
50
Research & Development
50
Clinical Trials
51
Epidemiology
52
Competitive Landscape
56
Research-Based Industry
56
Table: Multinational Market Activity
57
Generic Drugmakers
58
Pharmaceutical Distribution
59
Pharmaceutical Retail Sector
59
Company Profile
60
National Pharmaceutical Industries
60
Zynova/Oman Pharmaceutical Products Company
63
Demographic Forecast
66
Table: Population Headline Indicators (Oman 1990-2025)
67
Table: Key Population Ratios (Oman 1990-2025)
67
Table: Urban/Rural Population & Life Expectancy (Oman 1990-2025)
68
Table: Population By Age Group (Oman 1990-2025)
68
Table: Population By Age Group % (Oman 1990-2025)
69
Glossary
71
Methodology
73
Pharmaceutical Expenditure Forecast Model
73
Healthcare Expenditure Forecast Model
73
Notes On Methodology
74
Risk/Reward Index Methodology
75
Index Overview
76
Table: Pharmaceutical Risk/Reward Index Indicators
76
Indicator Weightings
77

The Oman Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Oman Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Oman pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Oman, to test other views - a key input for successful budgeting and strategic business planning in the Omani pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Omani pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Oman.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.